Everything below concerns pentadecapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-09. Numbers and descriptions here follow the published literature rather than marketing material.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
== Diagnosis == Skin changes, abnormal growth, and loss of hair occur. These symptoms normally start appearing by one year of age. A genetic test for LMNA mutations can confirm the diagnosis of progeria. Prior to the advent of the genetic test, misdiagnosis was common.
=== Law enforcement === GC–MS is increasingly used for detection of illegal narcotics, and may eventually supplant drug-sniffing dogs.[1] A simple and selective GC–MS method for detecting marijuana usage was recently developed by the Robert Koch Institute in Germany. It involves identifying an acid metabolite of tetrahydrocannabinol (THC), the active ingredient in marijuana, in urine samples by employing derivatization in the sample preparation. GC–MS is also commonly used in forensic toxicology to find drugs and/or poisons in biological specimens of suspects, victims, or the deceased. In drug screening, GC–MS methods frequently utilize liquid-liquid extraction as a part of sample preparation, in which target compounds are extracted from blood plasma.
Migraine without aura involves migraine headaches that are not accompanied by aura. Migraine with aura usually involves migraine headaches accompanied by aura. Less commonly, aura can occur without a headache or with a nonmigraine headache. Migraine with typical aura Migraine with brainstem aura (MBA), where a headache and aura are accompanied by difficulty speaking, world spinning, ringing in ears, or several other brainstem-related symptoms, but not motor weakness. Hemiplegic migraine and sporadic hemiplegic migraine, in which a person has migraine with aura and with accompanying motor weakness. If a close relative has had the same condition, it is called "familial"; otherwise, it is called "sporadic". Retinal migraine (which is distinct from visual or optical migraine) involves migraine headaches accompanied by visual disturbances or even temporary blindness in one eye. Chronic migraine is defined as headaches occurring on at least 15 days per month for more than three months, with at least eight days per month fulfilling criteria for migraine. Episodic syndromes that may be associated with migraine are often noted in childhood. These syndromes include cyclical vomiting (occasional intense periods of vomiting), abdominal migraine (abdominal pain, usually accompanied by nausea), and benign paroxysmal vertigo of childhood (occasional attacks of vertigo). Complications of migraine describe migraine headaches and/or auras that are unusually long or unusually frequent, or associated with a seizure or brain lesion.
Bone marrow transplant (heme-oncology intervention): The replacement of the bone marrow with bone marrow from an individual without spherocytosis. The transplanted progenitor cells do not have the genetic mutations found in individuals with hereditary spherocytosis, and therefore do not produce spherocytes. This results in an individual with biconcave-disc-shaped erythrocytes. This treatment is not standard of care, and is not offered as it has only been documented incidentally during treatment for other diseases, such as myelodysplastic syndrome. Symptomatic treatments:
A potential issue that arises through the use of NMR is low mass sensitivity, however this can be corrected for by employing microcoils that assist in distinguishing molecules of differing masses. This is necessary since the signal-to-noise ratio of sample sizes in the microliter to nanoliter range is dramatically reduced compared to bench-scale sample sizes, and microcoils have been shown to resolve this issue. Mass spectrometry (MS) and high-performance liquid chromatography (HPLC) have also been used to overcome this challenge. Although MS is an attractive analytical technique for distinguishing the products of reactions accomplished through DMF, it poses its own weaknesses. Matrix-assisted laser desorption ionization (MALDI) and electrospray ionization (ESI) MS have recently been paired with analyzing microfluidic chemical reactions. However, crystallization and dilution associated with these methods often leads to unfavorable side effects, such as sample loss and side reactions occurring. The use of MS in DMF is discussed in more detail in a later section.
Sources: en.wikipedia.org
In addition, several viruses, including the AIDS virus HIV, have binding sites for NF-κB that controls the expression of viral genes, which in turn contribute to viral replication or viral pathogenicity. In the case of HIV-1, activation of NF-κB may, at least in part, be involved in activation of the virus from a latent, inactive state. YopP is a factor secreted by Yersinia pestis, the causative agent of plague, that prevents the ubiquitination of IκB. This causes this pathogen to effectively inhibit the NF-κB pathway and thus block the immune response of a human infected with Yersinia.
== Fungi == Fungi can be used for many of the same processes as bacteria. For industrial applications, yeasts combine the bacterial advantages of being a single-celled organism that is easy to manipulate and grow with the advanced protein modifications found in eukaryotes. They can be used to produce large complex molecules for use in food, pharmaceuticals, hormones, and steroids. Yeast is important for wine production and as of 2016 two genetically modified yeasts involved in the fermentation of wine have been commercialized in the United States and Canada. One has increased malolactic fermentation efficiency, while the other prevents the production of dangerous ethyl carbamate compounds during fermentation. There have also been advances in the production of biofuel from genetically modified fungi. Fungi, being the most common pathogens of insects, make attractive biopesticides. Unlike bacteria and viruses they have the advantage of infecting the insects by contact alone, although they are out competed in efficiency by chemical pesticides. Genetic engineering can improve virulence, usually by adding more virulent proteins, increasing infection rate or enhancing spore persistence. Many of the disease carrying vectors are susceptible to entomopathogenic fungi. An attractive target for biological control are mosquitos, vectors for a range of deadly diseases, including malaria, yellow fever and dengue fever.
Sandoz also marketed and sold pure psilocybin under the name Indocybin to clinicians and researchers worldwide. There were no reports of serious complications when psilocybin was used in this way. In the early 1960s, Harvard University became a testing ground for psilocybin through the efforts of Timothy Leary and his associates Ralph Metzner and Richard Alpert (who later changed his name to Ram Dass). Leary obtained synthesized psilocybin from Hofmann through Sandoz Pharmaceuticals. Some studies, such as the Concord Prison Experiment, suggested promising results using psilocybin in clinical psychiatry. But according to a 2008 review of safety guidelines in human hallucinogenic research, Leary's and Alpert's well-publicized termination from Harvard and later advocacy of hallucinogen use "further undermined an objective scientific approach to studying these compounds". In response to concerns about the increase in unauthorized use of psychedelic drugs by the general public, psilocybin and other hallucinogenic drugs were unfavorably covered in the press and faced increasingly restrictive laws. In the U.S., laws passed in 1966 that prohibited the production, trade, or ingestion of hallucinogenic drugs; Sandoz stopped producing LSD and psilocybin the same year. In 1970, Congress passed "The Federal Comprehensive Drug Abuse Prevention and Control Act" that made LSD, peyote, psilocybin, and other hallucinogens illegal to use for any purpose, including scientific research.
Genome analysis reveal rifampicin resistant strains have a mutation in rpoA and rpoC. A similar study investigated the bacterial fitness associated with compensatory mutations in rifampin resistant Escherichia coli. Results obtained from this study demonstrate that drug resistance is linked to bacterial fitness as higher fitness costs are linked to greater transcription errors.
===== MeSH D08.811.682.690 – oxygenases ===== MeSH D08.811.682.690.416 – dioxygenases MeSH D08.811.682.690.416.277 – catechol 1,2-dioxygenase MeSH D08.811.682.690.416.305 – catechol 2,3-dioxygenase MeSH D08.811.682.690.416.319 – cysteine dioxygenase MeSH D08.811.682.690.416.326 – homogentisate 1,2-dioxygenase MeSH D08.811.682.690.416.328 – 3-hydroxyanthranilate 3,4-dioxygenase MeSH D08.811.682.690.416.330 – 4-hydroxyphenylpyruvate dioxygenase MeSH D08.811.682.690.416.333 – indoleamine-pyrrole 2,3-dioxygenase MeSH D08.811.682.690.416.444 – lipoxygenase MeSH D08.811.682.690.416.444.050 – arachidonate lipoxygenases MeSH D08.811.682.690.416.444.050.055 – arachidonate 5-lipoxygenase MeSH D08.811.682.690.416.444.050.060 – arachidonate 12-lipoxygenase MeSH D08.811.682.690.416.444.050.065 – arachidonate 15-lipoxygenase MeSH D08.811.682.690.416.444.525 – protocatechuate 3,4-dioxygenase MeSH D08.811.682.690.416.722 – tryptophan oxygenase MeSH D08.811.682.690.562 – inositol oxygenase MeSH D08.811.682.690.708 – mixed function oxygenases MeSH D08.811.682.690.708.062 – benzoate 4-monooxygenase MeSH D08.811.682.690.708.125 – catechol oxidase MeSH D08.811.682.690.708.125.500 – monophenol monooxygenase MeSH D08.811.682.690.708.170 – cytochrome p-450 enzyme system MeSH D08.811.682.690.708.170.040 – aryl hydrocarbon hydroxylases MeSH D08.811.682.690.708.170.040.024 – 7-alkoxycoumarin o-dealkylase MeSH D08.811.682.690.708.170.040.050 – aniline hydroxylase MeSH D08.811.682.690.708.170.040.110 – benzopyrene hydroxylase MeSH D08.811.682.690.708.170.040.332 – cytochrome p-450 cyp1a1 MeSH D08.811.682.690.708.170.040.443 – cytochrome p-450 cyp1a2 MeSH D08.811.682.690.708.170.040.499 – cytochrome p-450 cyp2b1 MeSH D08.811.682.690.708.170.040.555 – cytochrome p-450 cyp2d6 MeSH D08.811.682.690.708.170.040.777 – cytochrome p-450 cyp2e1 MeSH D08.811.682.690.708.170.040.888 – cytochrome p-450 cyp3a MeSH D08.811.682.690.708.170.085 – camphor 5-monooxygenase MeSH D08.811.682.690.708.170.500 – alkane 1-monooxygenase MeSH D08.811.682.690.708.170.915 – steroid hydroxylases MeSH D08.811.682.690.708.170.915.050 – aldosterone synthase MeSH D08.811.682.690.708.170.915.099 – aromatase MeSH D08.811.682.690.708.170.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.811.682.690.708.170.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.811.682.690.708.170.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.720 – steroid 11-beta-hydroxylase MeSH D08.811.682.690.708.170.915.730 – steroid 12-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.737 – steroid 16-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.748 – steroid 17-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.760 – steroid 21-hydroxylase MeSH D08.811.682.690.708.292 – dopamine beta-hydroxylase MeSH D08.811.682.690.708.392 – fatty acid desaturases MeSH D08.811.682.690.708.392.312 – beta-carotene 15,15'-monooxygenase MeSH D08.811.682.690.708.392.468 – Linoleoyl-CoA desaturase MeSH D08.811.682.690.708.392.625 – stearoyl-coa desaturase MeSH D08.811.682.690.708.401 – gamma-butyrobetaine dioxygenase MeSH D08.811.682.690.708.410 – heme oxygenase (decyclizing) MeSH D08.811.682.690.708.410.500 – heme oxygenase-1 MeSH D08.811.682.690.708.425 – 4-hydroxybenzoate 3-monooxygenase MeSH D08.811.682.690.708.557 – kynurenine 3-monooxygenase MeSH D08.811.682.690.708.601 – phenylalanine hydroxylase MeSH D08.811.682.690.708.660 – procollagen-lysine, 2-oxoglutarate 5-dioxygenase MeSH D08.811.682.690.708.673 – procollagen-proline dioxygenase MeSH D08.811.682.690.708.715 – prostaglandin-endoperoxide synthases MeSH D08.811.682.690.708.749 – squalene monooxygenase MeSH D08.811.682.690.708.783 – steroid hydroxylases MeSH D08.811.682.690.708.783.050 – aldosterone synthase MeSH D08.811.682.690.708.783.099 – aromatase MeSH D08.811.682.690.708.783.200 – cholesterol 7 alpha-hydroxylase MeSH D08.811.682.690.708.783.212 – cholesterol side-chain cleavage enzyme MeSH D08.811.682.690.708.783.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.811.682.690.708.783.720 – steroid 11-beta-hydroxylase MeSH D08.811.682.690.708.783.730 – steroid 12-alpha-hydroxylase MeSH D08.811.682.690.708.783.737 – steroid 16-alpha-hydroxylase MeSH D08.811.682.690.708.783.745 – steroid 17-alpha-hydroxylase MeSH D08.811.682.690.708.783.760 – steroid 21-hydroxylase MeSH D08.811.682.690.708.826 – trans-cinnamate 4-monooxygenase MeSH D08.811.682.690.708.870 – tryptophan hydroxylase MeSH D08.811.682.690.708.923 – tyrosine 3-monooxygenase
Sources: en.wikipedia.org
Colombia's varied cuisine is influenced by its diverse fauna and flora as well as the cultural traditions of the ethnic groups. Colombian dishes and ingredients vary widely by region. Some of the most common ingredients are: cereals such as rice and maize; tubers such as potato and cassava; assorted legumes; meats, including beef, chicken, pork and goat; fish; and seafood. Colombia cuisine also features a variety of tropical fruits such as cape gooseberry, feijoa, arazá, dragon fruit, mangosteen, granadilla, papaya, guava, mora (blackberry), lulo, soursop and passionfruit. Colombia is one of the world's largest consumers of fruit juices. Among the most representative appetizers and soups are patacones (fried green plantains), sancocho de gallina (chicken soup with root vegetables) and ajiaco (potato and corn soup). Representative snacks and breads are pandebono, arepas (corn cakes), aborrajados (fried sweet plantains with cheese), torta de choclo, empanadas and almojábanas. Representative main courses are bandeja paisa, lechona tolimense, mamona, tamales and fish dishes (such as arroz de lisa), especially in coastal regions where kibbeh, suero, costeño cheese and carimañolas are also eaten. Representative side dishes are papas chorreadas (potatoes with cheese), remolachas rellenas con huevo duro (beets stuffed with hard-boiled egg) and arroz con coco (coconut rice). Organic food is a current trend in big cities, although in general across the country the fruits and veggies are very natural and fresh.
On 19 June, Nasrallah stated that a Hezbollah invasion of the Galilee "remains on the table" and alleged that the government of Cyprus was allowing Israeli forces to operate within its country and thus made Cyprus a legitimate target for Hezbollah strikes. Cypriot president Nikos Christodoulides denied that Cyprus was taking sides in the conflict. On 30 June, Israeli officials reported 18 IDF soldiers were wounded by a drone attack on the Golan Heights. The inability of Israelis to return to settlements and homes in the north of the country led to Antony Blinken stating that Israel had effectively "lost sovereignty in the northern quadrant of its country". On 3 July, senior Hezbollah field commander Mohammed Nasser was killed in an Israeli airstrike in Tyre, and in response Hezbollah fired 100 rockets at IDF positions. The following day, it fired 200 more rockets into Israel. On 9 July, an Israeli airstrike on the Beirut–Damascus highway in Syria killed two Hezbollah members, and Hezbollah fired 40 rockets at the Golan Heights. A week later, at least two people were wounded in an Israeli drone attack in Lebanon, and Hezbollah rocket strikes in Kiryat Shmona damaged residential buildings. On 22 July, drones from Lebanon were intercepted by Israeli forces, and a Hezbollah rocket strike injured two soldiers in northern Israel. The following day and in response, Israel launched artillery strikes on southern Lebanon, Hezbollah launched rocket strikes in northern Israel, and Israeli warplanes and artillery struck southern Lebanon.
More than half of all business incubation programs are "mixed-use" projects, meaning they work with clients from a variety of industries. Technology incubators account for 39% of incubation programs. One example of a specialized type of incubator is a bio incubator. Bioincubators specialize in supporting life science-based startup companies. Entrepreneurs with feasible projects in life sciences are selected and admitted to these programs.
The composition and rate of CSF generation are influenced by hormones and the content and pressure of blood and CSF. For example, when CSF pressure is higher, there is less of a pressure difference between the capillary blood in choroid plexuses and CSF, decreasing the rate at which fluids move into the choroid plexus and CSF generation. The autonomic nervous system influences choroid plexus CSF secretion, with activation of the sympathetic nervous system decreasing secretion and the parasympathetic nervous system increasing it. Changes in the pH of the blood can affect the activity of carbonic anhydrase, and some drugs (such as furosemide, acting on the Na-K-Cl cotransporter) have the potential to impact membrane channels.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.